Excessive daytime sleepiness (EDS) affects a large percentage of Parkinson's disease (PD) patients, and it is enhanced by dopamine agonist drugs. Currently, there is no treatment of choice for EDS in PD. Our aim was to check the clinical impression that some patients who were given selegiline, a selective inhibitor of monoamine oxidase B, experienced an improvement in their daytime somnolence.

Selegiline reduces daytime sleepiness in patients with Parkinson's disease

Gallazzi, Marco
Primo
;
Mauri, Marco
Secondo
;
Princiotta Cariddi, Lucia;Carimati, Federico;Versino, Maurizio
Ultimo
2021

Abstract

Excessive daytime sleepiness (EDS) affects a large percentage of Parkinson's disease (PD) patients, and it is enhanced by dopamine agonist drugs. Currently, there is no treatment of choice for EDS in PD. Our aim was to check the clinical impression that some patients who were given selegiline, a selective inhibitor of monoamine oxidase B, experienced an improvement in their daytime somnolence.
Parkinson’s disease; Selegiline; sleepiness
Gallazzi, Marco; Mauri, Marco; Bianchi, Maria Laura; Riboldazzi, Giulio; Princiotta Cariddi, Lucia; Carimati, Federico; Rebecchi, Valentina; Versino, Maurizio
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11383/2108944
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 4
social impact